Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone

Objective: To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS). Design: Case report. Setting: Academic clinical practice and General Clinical Research Center. Patient(s): A 25-year-old woman with PCOS. Intervention(s): Rosiglitazone maleate, 4 mg daily for 5 months until conception. Main Outcome Measure(s): Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images. Result(s): Rosiglitazone. treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception. Conclusion(s): Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted. (C) 2001 by American Society for Reproductive Medicine.